Women with high-risk HER2-positive breast cancer lived significantly ... "We know that patients who achieve a pathologic complete response [pCR] with neoadjuvant therapy do quite well and they ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

HER2-positive breast cancer may be a misnomer, according to a growing body of evidence that one of the most widely recognized oncogenes, HER2, may not be the primary driver of the disease. The ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.

The relatively recent development of hormone receptors and human epidermal growth factor receptor 2 (HER2) as validated targets ... because of low pCR rates, although this evidence is generally ...

The pCR rate in patients treated with the PARP inhibitor ... More information: Guillermo Villacampa et al, RAD51 testing in patients with early HER2-negative breast cancer and homologous ...

Then for those patients who didn't get to pCR, we can give more intensive treatment ... has compiled an impressive record as treatment for HER2-positive breast cancer. The agent outperformed ...

Subscribe for FREE Overall, pCR rates were 25% in the trial participants treated ... There were no deaths in the placebo arm. ER+/HER2− breast cancer accounts for 70% of the around 2.3 million cases ...